{{Rsnum
|rsid=1934968
|Gene=CYP2C9
|Chromosome=10
|position=96741817
|Orientation=plus
|GMAF=0.1465
|Gene_s=CYP2C9
|Assembly=GRCh37.p5
|GenomeBuild=37.3
|dbSNPBuild=135
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 1.8 | 16.8 | 81.4
| HCB | 11.7 | 49.6 | 38.7
| JPT | 11.5 | 40.7 | 47.8
| YRI | 0.0 | 0.0 | 100.0
| ASW | 0.0 | 5.3 | 94.7
| CHB | 11.7 | 49.6 | 38.7
| CHD | 20.4 | 47.2 | 32.4
| GIH | 0.0 | 18.8 | 81.2
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 22.4 | 77.6
| MKK | 0.0 | 0.6 | 99.4
| TSI | 1.0 | 16.7 | 82.4
| HapMapRevision=28
}}{{PMID Auto
|PMID=22321278
|Title=[Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy]
}}

{{PMID Auto
|PMID=22178823
|Title=[Distribution of variant alleles association with warfarin pharmacokinetics and pharmacodynamics in the Han population in China].
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA}}
{{on chip | Illumina Human 1M}}